Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...

Over the twelve months to December 2024, Gilead Sciences recorded an accrual ratio of -0.27. That implies it has very good cash conversion, and that its earnings in the last year actually ...

Have you been paying attention to shares of Gilead Sciences (GILD)? Shares have been on the move with the stock up 17.1% over the past month. The stock hit a new 52-week high of $117.39 in the ...

Gilead Sciences has a 52-week low of $62.07 and a 52-week high of $111.03. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Stock analysts at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Gilead Sciences in a research report ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.

Deutsche Bank upgraded Gilead Sciences (NASDAQ:GILD) on Tuesday, citing the antiviral developer’s HIV treatment franchise, and downgraded Merck (NYSE:MRK), citing the cancer drugmaker’s ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Kennet Brysting, president of Gilead Sciences Japan, mentioned an intriguing possibility during an interview in Tokyo late last year. “I do believe that Japan could be one of the first countries ...